Yahoo · Sep 11, 2026
Second Time’s The Charm: FDA Clears Scholar Rock’s SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours
FDA approved Isembyld for patients age two and older who already take certain spinal muscular atrophy drugs.
SR
NASDAQ · SRRK
Scholar Rock Holding Corporation
Healthcare · Biotechnology
$50.00
Down-$1.85 (-3.57%)
Updated Sep 16, 2026, 10:57 AM
SID Score
5.6/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 4.78B
- P/E ratio
- -15.08
- Dividend yield
- 0.00%
- 52-week range
- $27.07 – $61.76
- Volume
- 5.25M
- Avg. volume
- 2.6M
Price performance
SRRK price history
1M range · 20 trading sessions · Daily adjusted prices
SRRK closed at $50.00 after 20 trading sessions, down 8.63% for the selected period.
- Last close
- $50.00
- Period change
- -8.63%
- Period low
- $50.00
- Period high
- $60.04
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $50.775 | $51.1067 | $46.54 | $50.00 | 5.25M |
| Sep 14, 2026 | $56.505 | $56.90 | $51.58 | $51.85 | 4.05M |
| Sep 11, 2026 | $55.67 | $56.935 | $54.91 | $55.41 | 994.4K |
| Sep 10, 2026 | $54.01 | $56.71 | $53.86 | $55.67 | 1.18M |
| Sep 9, 2026 | $57.30 | $57.65 | $54.44 | $54.62 | 1.6M |
| Sep 8, 2026 | $54.088 | $57.79 | $54.00 | $57.42 | 1.84M |
| Sep 4, 2026 | $55.08 | $55.98 | $55.00 | $55.33 | 658.05K |
| Sep 3, 2026 | $56.14 | $56.24 | $55.00 | $55.94 | 803.49K |
| Sep 2, 2026 | $56.62 | $58.10 | $55.2701 | $56.10 | 1.07M |
| Sep 1, 2026 | $56.45 | $57.70 | $55.33 | $55.89 | 763.19K |
| Aug 31, 2026 | $57.20 | $57.815 | $56.10 | $56.80 | 987.26K |
| Aug 28, 2026 | $58.75 | $59.30 | $57.17 | $57.80 | 809.72K |
| Aug 27, 2026 | $60.00 | $60.175 | $58.87 | $59.26 | 620.74K |
| Aug 26, 2026 | $58.25 | $61.76 | $57.61 | $60.04 | 2.28M |
| Aug 25, 2026 | $58.20 | $59.48 | $57.06 | $58.25 | 1.21M |
| Aug 24, 2026 | $56.80 | $58.75 | $55.90 | $58.20 | 1.22M |
| Aug 21, 2026 | $55.38 | $57.10 | $54.98 | $56.50 | 1.16M |
| Aug 20, 2026 | $55.93 | $56.75 | $54.84 | $55.25 | 1.53M |
| Aug 19, 2026 | $56.13 | $57.15 | $54.09 | $56.51 | 1.33M |
| Aug 18, 2026 | $51.91 | $54.78 | $51.91 | $54.72 | 1.22M |
Latest SRRK news
The latest Smart Investors Daily articles mentioning SRRK.
Stock researchCompany · Overview
SRRK research
Overview
Company profile and research snapshot.
Company profile
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $49.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 15, 2026 | Wedbush | Outperform | — |
| Sep 15, 2026 | Barclays | Equal-Weight | — |
| Sep 15, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 14, 2026 | Truist Securities | Buy | — |
| Sep 14, 2026 | BMO Capital | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 11, 2026
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass., September 11, 2026--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced that the FDA has approved ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults and children two years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targete
Benzinga · Sep 11, 2026
FDA Approves First Therapy To Target Muscle Loss In Spinal Muscular Atrophy In Patients Aged 2 Years And Older
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-therapy-target-muscle-loss-spinal-muscular-atrophy
SeekingAlpha · Sep 10, 2026
Scholar Rock Holding Corporation (SRRK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Scholar Rock Holding Corporation (SRRK) Citigroup's Biopharma Back to School Summit 2026 September 10, 2026 9:20 AM EDTCompany ParticipantsDavid Hallal -...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
